GILD - Gilead Sciences
92.57
| Index: | NDX, S&P 500 | P/E: | 1043.63 | EPS (ttm): | 0.09 | Insider Own: | 0.10% | Shs Outstand: | 1.25B | Perf Week: | 0.78% |
| Market Cap: | 117.24B | Forward P/E: | 12.23 | EPS next Y: | 7.57 | Insider Trans: | -29.44% | Shs Float: | 1.24B | Perf Month: | 4.45% |
| Income(ttm): | 126.00M | PEG: | 111.52 | EPS next Q: | 1.72 | Inst Own: | 85.34% | Short Float: | 1.88% | Perf Quarter: | 10.22% |
| Revenue(ttm): | 28.27B | P/S: | 4.15 | EPS this Y: | -34.72% | Inst Trans: | 0.47% | Short Ratio: | 3.48 | Perf Half Y: | 30.88% |
| Book/sh: | 14.83 | P/B: | 6.24 | EPS next Y: | 72.59% | ROA: | 0.22% | Short Interest: | 23.41M | Perf Year: | 17.79% |
| Cash/sh: | 5.29 | P/C: | 17.51 | EPS next 5Y: | 9.36% | ROE: | 0.62% | 52W Range: | 62.07 - 98.90 | Perf YTD: | 14.27% |
| Dividend Est.: | 3.06 (3.31%) | P/FCF: | 12.43 | EPS past 5Y: | 1.55% | ROI: | 0.32% | 52W High: | -6.40% | Beta: | 0.20 |
| Dividend TTM: | 3.08 (3.33%) | Quick Ratio: | 1.10 | Sales past 5Y: | 4.16% | Gross Margin: | 77.96% | 52W Low: | 49.14% | ATR (14): | 2.08 |
| Dividend Ex-Date: | Dec 13, 2024 | Current Ratio: | 1.26 | EPS Y/Y TTM: | -97.87% | Oper. Margin: | 37.45% | RSI (14): | 54.42 | Volatility: | 2.15% 2.20% |
| Employees: | 18000 | Debt/Eq: | 1.26 | Sales Y/Y TTM: | 3.72% | Profit Margin: | 0.45% | Recom: | 1.97 | Target Price: | 99.21 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 1.16 | EPS Q/Q: | -42.06% | Payout: | 66.62% | Rel Volume: | 3.35 | Prev Close: | 91.09 |
| Sales Surprise: | 7.55% | EPS Surprise: | 32.03% | Sales Q/Q: | 7.05% | Earnings: | Nov 06 AMC | Avg Volume: | 6.73M | Price: | 92.57 |
| SMA20: | 0.65% | SMA50: | 2.30% | SMA200: | 20.24% | Undervalued: 7.17% | Volume: | 22,529,402 | Change: | 1.62% | |
Graham Classic formula value: 2.2
(P/E=8 * 1g) Min value: 1.4
(current P/E * 2g) Max value: 85.86
Average value: 29.82
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.